By C.R. Jackson:
Versartis, Inc., (NASDAQ:VSAR) is a $540M market cap biopharmaceutical company that is developing therapeutic proteins to treat metabolic diseases and endocrine disorders.
The company's most advanced product candidate is VRS-317, a human growth hormone. VRS-317 is a fusion protein consisting of recombinant human growth hormone (rhGH). VRS-317 has successfully completed a Phase 2 trial as a therapy for pediatric growth hormone deficiency, and is scheduled to begin a Phase 3 trial next year. The company plans to implement a Phase 2/Phase 3 trial to investigate VRS-317 as a treatment for adult growth hormone deficiency in 2015. Versartis researchers are also studying VRS-317 as a therapy for idiopathic short stature and Turner syndrome.
The company also has rights to a proprietary half-life extension technology known as XTEN, which is in-licensed from Amunix Operating, Inc., a privately held company based in Mountain View, California. By extending the
Complete Story ยป